Covid19: Roche-Cipla antibody cocktail launched in India at Rs 59,750 per dose

It is to be administered for the treatment of mild to moderate Covid 19 patients who are at high risk.

The pharma company Roche and Cipla announced the launch of the first Antibody Cocktail in India. The antibody cocktail is priced at Rs 59,750 per dose.

It is to be administered for the treatment of mild to moderate Covid 19 patients who are at high risk. In a joint statement, Cipla Limited and Roche India said, “The first batch of Antibody Cocktail (Casirivimab and Imdevimab) is now available in India whole a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment of two patients.”

The cocktail has proved to help high-risk patients. The antibody cocktail will reduce the risk of hospitalization and fatality by 70 percent. It can be used in the treatment of adults and pediatric patients (12 years of age or older, weighing at least 40kg) as well.

Also Read: Effect of Covid vaccine likely to last for years, Scientists suggest booster dose to increase immunity

Indian drugmaker Cipla will distribute it by leveraging its strong distribution strengths across the country.

The dose for a single patient i.e. 1200mg will include 600mg of Casirivimab and 600mg of Imdevimab. It will cost Rs 59,750 inclusive of all taxes and the maximum retail price for the multi-dose pack is Rs 1,19,500 inclusive of all taxes.

“We are optimistic that the availability of Antibody cocktail in India and help in minimizing hospitalization, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens,” V Simpson Emmanuel, Managing director and CEO of Roche Pharma said.

Get the latest update about current news in india, check out more about india news, india news online, first Antibody Cocktail in India & reduce risk of hospitalization

Like us on Facebook or follow us on Twitter for more updates.